Case-Based Roundtable Meetings Spotlight June 2021: Solid Tumors

During a Targeted Oncology Case-Based Roundtable event, Vadim S. Koshkin, MD, discussed switch maintenance for patients with bladder cancer.

Strategies for treating patients with HER2-positive breast cancer and metastatic brain lesions was a topic discussed between William J. Gradishar, MD, and a group of peers during a Targeted Oncology Case-Based Roundtable event.

During a Targeted Oncology Case-Based Roundtable event, Daniel A. Landau, MD, moderated a discussion around the JAVELIN trial and how its results were practice changing for oncologists treating for bladder cancer.

Based on clinical trial data, apalutamide, enzalutamide, and darolutamide are all viable treatment options for nonmetastatic castration resistant prostate cancer.

Eric Nadler, MD, MPP, lead a Cased-Based Roundtable event during which participants discussed how PD-L1 expression in patient with non–small cell lung cancer impacts treatment decisions.

Both selpercatinib and pralsetinib are FDA-approved therapies for RET-altered medullary thyroid cancer. The research supporting both agents and the experience with their use in clinical practice was the topic of a recent Case-Based Roundtable event moderated by Marcia S. Brose, MD, PhD.

During a Targeted Oncology Case-Based Roundtable event, Catherine Shu, MD, moderated a discussion around the case of a 77-year-old patients with non–small cell lung cancer.

During a Targeted Oncology Case-Based Roundtable event, Jessica Bauman, MD, discussed the case of 59-year-old patient with RET-mutated non–small cell lung cancer.

During a Targeted Oncology Case-Based Roundtable event, Joyce A. O’Shaughnessy, MD, discussed the case of a 63-year-old woman with HER2-positive breast cancer.

Ticiana Leal, MD, explained her approach to treating a patient with extensive-stage small cell lung cancer, during a Targeted Oncology Case-Based Roundtable event.

During a Targeted Oncology Case-Based Roundtable event, Michael K. Wong, MD, PhD, discussed the case of a 69-year-old patient with cutaneous squamous cell carcinoma.

During a Targeted Oncology Case-Based Roundtable event, David I. Quinn, MD, PhD, MBBS leads a discussion on treatment for metastatic castration-resistant prostate cancer following frontline treatment.

Many options are available for the treatment of RET-mutated thyroid cancer. During a Targeted Oncology Case-Based Roundtable event, Francis Paul Worden, MD, discussed the case of a 58-year-old patients who first presented with solitary nodule on the neck, occasional shortness of breath, and intermittent excessive fatigue.

Treatment of patients with EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA clinical trial resulted in practice-changing disease-free survival with tolerable safety.

During a Targeted Oncology Case-Based Roundtable event, Mark A. Socinski, MD, discussed the case of a 59-year-old patients with non–small cell lung cancer.